Case report

Unilateral methotrexate-induced lung injury with foreign bodies in the airway: A case report

Haruyasu Sakuranaka a,*, Takashi Nakagawa a, b, Shun Yokota b, Eichi Takahashi a, b, Yuji Yamakawa a, Akifumi Hirata b, Koumei Igei a, b, Naoki Okamoto a, Masahiko Ichioka a

a Department of Respiratory Medicine, Toshima Hospital, Tokyo Metropolitan Health and Hospitals Corporation, 33-1, Sakaecho, Itabashi-Ku, Tokyo, 173-0015, Japan
b Department of Internal Medicine, Division of Respiratory Medicine, Nihon University School of Medicine, 30-1, Oyaguchikamicho, Itabashi-Ku, Tokyo, 173-8601, Japan

ARTICLE INFO

Keywords:
Unilateral
Methotrexate
Drug-induced lung injury
Airway foreign body
Pneumonia
Interstitial lung disease

ABSTRACT

A 75-year-old woman who had been taking methotrexate presented to our hospital for fever and dry cough. Chest computed tomography showed ground-glass opacity in the upper lobe of the right lung and foreign bodies in the lower lobe of the right bronchus. During bronchoscopy, foreign bodies were removed from the airway. We found increased levels of lymphocytes and a high CD4/CD8 ratio in the bronchoalveolar lavage fluid. Transbronchial lung biopsy revealed lymphocytic infiltration. Methotrexate was discontinued, and the imaging findings improved. Methotrexate-induced lung injury does occur unilaterally. Foreign bodies in the airway might also trigger unilateral methotrexate-induced lung injury.

1. Introduction

Methotrexate (MTX) is used for rheumatoid arthritis and for leukemia, as well as other malignancies. MTX-induced lung injury (MTX-ILI) is a widely known adverse event. Like other drug-ILIs, almost all cases of MTX-ILI manifest radiologically with shadows in both lungs [1]. Unilateral drug-ILI has been very rare; it was often clinically diagnosed due to inadequate examinations in the past. Drug-ILI is difficult to diagnose because no diagnostic method is specific to this condition, and whether drug-ILI can be unilateral has been unclear. Also, drug-ILI with concomitant foreign bodies in the airways has not been described previously. We report a case of unilateral MTX-ILI in which adequate examination was performed, and the radiological lung shadow improved only after discontinuation of MTX. In our patient, unilateral MTX-ILI occurred after aspiration of foreign bodies. We describe the relationship between unilateral drug-ILI and foreign bodies in the airways and review the related literature.

2. Case presentation

A 75-year-old woman had been taking MTX for 2 years for rheumatoid arthritis. She presented with a fever and a dry cough that had started after dinner. The next day, a chest x-ray showed a ground-glass opacity in the right upper lung field (Fig. 1A). A general...
Fig. 1. Chest x-rays showing an enlarged ground-glass opacity in the right upper lung field. (A) 5 days before hospital admission. (B) The day of hospital admission.

Table 1
Results of laboratory tests on hospital admission.

| Hematologic findings | Serologic findings | BALF results (right lung B³) |
|----------------------|---------------------|-----------------------------|
|                      | WBC count  6000 /µL | C-reactive protein 14.0 mg/dL | Recovery 86/150 mL |
| Neutrophils 86.7 %   | IgG 1324 mg/dL      | WBC count 3.8 × 10² /mL     |
| Lymphocytes 7.6 %    | IgA 192 mg/dL       | Neutrophils 4 %             |
| Monocytes 5.0 %      | IgM 66 mg/dL        | Lymphocytes 35 %            |
| Eosinophils 0.5 %    | 50% complement activity 65 IU/mL | Esinophils 3 % |
| Basophils 0.2 %      | Rheumatoid factor 9 IU/mL | Macrophages 58 % |
| RBC count 363 × 10¹/µL | Antinuclear antibodies <40 × | CD4/CD8 4.62 |
| Hemoglobin 11.3 g/dL | Proteinase 3 ANCA <10 U/mL | Culture – |
| Hematocrit 33.7 %    | Myeloperoxidase ANCA <10 U/mL | – |
| Platelet count 27.0 × 10¹/µL | KL-6 269 U/mL | TB PCR – |

| Biochemistry findings | Surfactant protein D 149 ng/mL | B-type natriuretic peptide 57.3 pg/mL | Mycoplasma pneumoniae Ab <40 × |
|-----------------------|---------------------------------|----------------------------------------|---------------------------------|
| Total protein 7.0 g/dL| Mycoplasma pneumoniae IgM 0.29 | Methotrexate + | DLST |
| Albumin 3.3 g/dL      | C. pneumoniae IgA 2.90 | – |
| Aspartate aminotransferase 24 IU/L | C. pneumoniae IgG 2.21 | Blood culture – |
| Alanine aminotransferase 15 IU/L | Chlamydia psittaci Ab – | Sputum culture Normal flora |
| γ-Glutamyl transpeptidase 29 IU/L | Candida antigen – | – |
| Alkaline phosphatase 286 IU/L | Aspergillus antigen – | – |
| Lactate dehydrogenase 246 IU/L | Cryptococcus antigen – | – |
| Blood urea nitrogen 22.2 mg/dL | β-D-glucan – | – |
| Creatinine 0.52 mg/dL | CMV pp65 antigen C7HRP – | – |
| Sodium 133 mEq/L      | T-SPOT.TB test –  | – |
| Potassium 4.7 mEq/L   | Urinary antigen – | – |
| Chlorine 95 mEq/L     | Streptococcus pneumoniae – | – |
| Fasting blood glucose 105 mg/dL | Legionella pneumophila – | – |
| Hemoglobin A1c 4.8 %  | – | – |

WBC, white blood cell; RBC, red blood cell; Ig, Immunoglobulin; ANCA, antineutrophil cytoplasmic antibodies; KL-6, Krebs von den Lungen 6; Ab, antibody; PCR, polymerase chain reaction; CMV, cytomegalovirus; TB, tuberculosis; MAC, Mycobacterium avium-Mycobacterium intracellulare complex; BALF, bronchoalveolar lavage fluid; DLST drug lymphocyte stimulation test.
Fig. 2. Chest CT showing a ground-glass opacity in the upper lobe of the right lung and foreign bodies in the lower lobe of the right bronchus (arrow).

Fig. 3. Bronchoscopic view showing white foreign bodies in the basal segment of the right bronchus.

Fig. 4. Foreign bodies in the airway. Inside the dense cluster of chamber-like structures surrounded by wall-like structures, a small number of eosinophilic spherical structures are found. Plant seeds are suspicious but are difficult to identify due to the lack of shells.
practitioner diagnosed that she had a *Mycoplasma pneumoniae* infection, and she was prescribed clarithromycin, 400 mg/day.

Five days later, because the fever and dry cough persisted, she was admitted to our hospital. Physical examination revealed a temperature of 38.0 °C, a respiratory rate of 20/minute, and room-air oxygen saturation of 96%. Fine crackles were heard in the right anterior part of the chest. A chest x-ray showed an enlarged ground-glass opacity in the right upper lung field (Fig. 1B).

Laboratory tests revealed a C-reactive protein level of 14.0 mg/dL, a Krebs von den Lungen 6 (KL-6) level of 269 U/mL, and a surfactant protein D level of 149 ng/mL. Crucial findings were that *Mycoplasma pneumoniae* antibody, *Chlamydia pneumoniae* immunoglobulin M, *Chlamydia psittaci* antibody, *Legionella pneumophila* antigen, *Streptococcus pneumoniae* antigen, β-D-glucan, *Candida* antigen, *Aspergillus* antigen, *Cryptococcus* antigen, and cytomegalovirus pp65 antigen C7HRP (cytomegalovirus antigenemia) were not present, and results of the T-SPOT.TB test (tuberculosis-specific interferon-γ) and blood cultures were all negative. The drug lymphocyte stimulation test (DLST) yielded positive results for MTX (Table 1).

Chest computed tomography (CT) showed a ground-glass opacity in the upper lobe of the right lung and foreign bodies in the lower lobe of the right lung. An enlarged ground-glass opacity was noted in the right upper lobe (Fig. 1B). Transbronchial biopsy specimen shows lymphocytic infiltration and fibrous thickening of the septum (hematoxylin and eosin stain) (Fig. 5).

Contrast-enhanced chest CT on the 26th day shows only a slight scar in the upper lobe of the right lung and no blood flow disruption. The methotrexate has only been discontinued. Following a discontinuity of methotrexate, the ground-glass opacity in the right upper lung field has gradually disappeared (Fig. 6).

![Transbronchial biopsy specimen shows lymphocytic infiltration and fibrous thickening of the septum](image1.png)

![Contrast-enhanced chest CT on the 26th day shows only a slight scar in the upper lobe of the right lung](image2.png)
### Table 2

Clinical characteristics of all reported cases of unilateral drug-induced lung injury.

| Case no. | Age, sex | Drug               | Background                          | CT findings | BALF findings       | TBLB findings              | Reference |
|----------|----------|--------------------|-------------------------------------|-------------|---------------------|----------------------------|-----------|
| 1        | 54, F    | Methotrexate       | Squamous cell lung carcinoma        | –           | –                   | Inflammatory cell infiltration | 2         |
| 2        | 71, M    | Amiodarone         | Ventricular tachycardia             | –           | Mild increase in neutrophils | Fibrous thickening of the septum | 8         |
| 3        | 78, M    | Amiodarone         | Ventricular tachycardia             | Consolidation | Mild increase in neutrophils | Non-specific inflammation | 9         |
| 4        | 44, F    | Balsalazide        | Ulcerative colitis                  | Consolidation | –                   | Organizing pneumonia        | 10        |
| 5        | 53, F    | Mesalamine         | Ulcerative colitis                  | –           | Increase in eosinophils | Eosinophilic pneumonia      | 11        |
| 6        | 49, F    | Nivolumab          | Endometrial cancer                  | Opacity     | Neutrophils and lymphocytes | – | 12        |
| 7        | 76, M    | Loxoprofen         | Lung adenocarcinoma (postoperative finding) | Opacity     | Increase in eosinophils | – | 13        |
| 8        | 74, F    | Meropenem          | Lung adenocarcinoma (postoperative finding) | Consolidation | Opacity | Increase in eosinophils | – | 14        |
| 9        | 81, F    | Fibrin sealant     | Lung adenocarcinoma (postoperative finding) | Opacity     | Increase in eosinophils | – | 15        |
| 10       | 73, M    | Amoxicillin/sulbactam | Mycoplasma pneumonia             | –           | –                   | – | 16        |
| 11       | 54, F    | Sirolimus          | Cadaveric renal transplantation     | Consolidation | Opacity | Mild increase in neutrophils | Organizing pneumonia | 17        |
| 12       | 53, M    | Mitomycin, Vindesine, Cisplatin | Squamous cell lung carcinoma   | Opacity     | –                   | – | 18        |
| Our patient | 75, F | Methotrexate       | Rheumatoid arthritis, Airway foreign bodies | Opacity     | Increase in lymphocytes | Lymphocytic infiltration | Fibrous thickening of the septum | 2         |

CT, computed tomography; BALF, bronchoalveolar lavage fluid; TBLB, transbronchial lung biopsy.
lobe of the right bronchus (Fig. 2).

A bronchoscopy revealed white foreign bodies in the right bronchus basal segment, which we removed with biopsy forceps (Fig. 3).

Pathological examination demonstrated a small number of eosinophilic spherical structures inside a dense cluster of chamber-like structures surrounded by wall-like structures. We suspected that the spherical structures represented some plant seed, but it was difficult to identify because of the lack of shells (Fig. 4).

Bronchoalveolar lavage fluid (BALF) from the right lung B\(^3\) showed a total cell count of 3.8 \(\times\) 10\(^5\)/mL (4% neutrophils, 35% lymphocytes, 3% eosinophils, 58% macrophages, and a CD4/CD8 ratio of 4.62), and cultures of BALF yielded negative results. Transbronchial lung biopsy from the right lung B\(^2\) demonstrated lymphocytic infiltration and fibrous thickening of the septum. No neutrophilic infiltration, granuloma, or giant cells representing phagocytosis of foreign bodies were found (Fig. 5).

After hospitalization, MTX therapy was discontinued, and the ground-glass opacity in the upper lobe of the right lung gradually disappeared without corticosteroids or any other antibiotics. The contrast medium-enhanced CT on the 26th day showed only a slight scar in the right lung’s upper lobe and no disruption of blood flow (Fig. 6).

She was discharged from the hospital in good health and with stable respiratory status on the 28th day.

3. Discussion

MTX-ILI is a widely known adverse event like other drug-ILIs. MTX-ILI typically manifests radiologically with shadows in both lungs [1]. One case of unilateral MTX-ILI was reported previously [2], in which a physician evaluation with bronchoscopy was performed, but the only laboratory tests performed were complete blood cell counts and urinalysis. No diagnostic method is specific for drug-ILI [3]. Thus, it is important to rule out other diseases, discontinue the suspect drug in hopes of improving imaging findings, and worsen the condition by readministering the drug. In MTX-ILI, the appearance of new shadows on imaging studies, the absence of causal organisms in blood and sputum, and the pathological findings are especially important [3]. DLST is an available adjunct diagnostic test, but DLST for MTX has low specificity and yields many false-positive results [4]. In patients with MTX-ILI, BALF demonstrates increases in lymphocyte levels and a high CD4/CD8 ratio. Because the CD4/CD8 ratio is low in patients with other drug-ILIs, such as interstitial lung disease, a high CD4/CD8 ratio is of great diagnostic significance in MTX-ILI [5]. The main pathological findings of MTX-ILI are interstitial infiltration by lymphocytes, histiocytes, and eosinophils, with or without granulomas [6].

No findings were suggestive of atypical pneumonia, antimicrobial infection, fungal infection, pneumocystis pneumonia, or cytomegalovirus infection in our patient. Although the results of DLST were positive for MTX, these did not confirm MTX-ILI yet. The patient’s BALF exhibited characteristic increases in lymphocyte levels and a high CD4/CD8 ratio, and transbronchial lung biopsy revealed lymphocytic infiltration. Discontinuation of MTX seems to have resulted in improvement in the ground-glass opacity of the right lung. In our patient, MTX was not readministered. MTX-ILI is thought to be a hypersensitivity reaction, and relapse does not often occur with readministration [7].

Although unilateral drug-ILI has often been reported, many affected patients have, in fact, exhibited lesions in both lungs [1]. Only 12 cases of actual unilateral drug-ILI have been previously reported (Table 2) [2,8–18]; of these, one case involved MTX [2], two involved amiodarone [8,9], and one each involved balsalazide [10] and mesalamine [19] (both of which are 5-aminosalicylic acid drugs). These medications are often reported to cause drug-ILI, and patients who take them may also be prone to unilateral drug-ILI. In one case of unilateral nivolumab-ILI, aspiration of saliva or blood may have been the trigger [12]. In addition, three cases of unilateral drug-ILI were reported after surgery for lung cancer [13–15]. After surgery, immune cells are stimulated, and inflammatory cytokines are released. Goda et al., therefore, hypothesized that the residual postoperative lung is more prone to drug-ILI, in view of the inflammatory cytokine release [14].

In our patient, MTX-ILI developed 2 years after MTX treatment and had an acute presentation after aspiration of foreign bodies. Previous reports have shown that aspiration and surgery, which increase inflammatory cytokines, can lead to unilateral drug-ILI. In addition, foreign bodies in the airways, especially organic foreign bodies, can increase the expression of inflammatory cytokines [19,20]. Therefore, we hypothesized that unilateral MTX-ILI was secondary to aspiration of the airway foreign bodies, which increased the expression of inflammatory cytokines. We found no previous reports of concomitant foreign bodies in the airways and drug-ILI. Our patient might represent the first case in which foreign bodies in the airways, especially organic ones, have caused unilateral drug-ILI. Further investigations are needed to elucidate the relationship between unilateral drug-ILI and foreign bodies in the airways.

4. Conclusion

MTX-ILI does occur unilaterally. Foreign bodies in the airways might also trigger unilateral MTX-ILI.

Funding

Not applicable.

Declarations of competing interest

The authors declare that they have no competing interests.

Acknowledgements

Not applicable.
References

[1] E.C. Rosenow 3rd, A.H. Limper, Drug-induced pulmonary disease, Semin. Respir. Infect. 10 (1995) 86–95.
[2] P.K. Rohatgi, L. Halvarson, Unilateral methotrexate-induced pneumonitis, J. Natl. Med. Assoc. 72 (1980) 896–899.
[3] S.A. Al Nokhatha, R. Harrington, R. Conway, Methotrexate and the lung in rheumatoid arthritis, Eur. Med. J. Rheumatol. 7 (2020) 80–90.
[4] S. Hirata, N. Hattori, K. Kumagai, Y. Haruta, A. Yokoyama, N. Kohno, Lymphocyte transformation test is not helpful for the diagnosis of methotrexate-induced pneumonitis in patients with rheumatoid arthritis, J. Clin. Acta 407 (2009) 25–29.
[5] A. Schnabel, C. Richter, S. Bauerfeind, W.L. Gross, Bronchoalveolar lavage cell profile in methotrexate induced pneumonitis, Thorax 52 (1997) 377–379.
[6] G.E. Fragoulis, E. Nikiforou, J. Larsen, P. Korsten, R. Conway, Methotrexate-associated pneumonitis and rheumatoid arthritis-interstitial lung disease: current concepts for the diagnosis and treatment, Front. Med. 6 (2019) 238.
[7] N.J. Cook, G.J. Carroll, Successful reintroduction of methotrexate after pneumonitis in two patients with rheumatoid arthritis, Ann. Rheum. Dis. 51 (1992) 272–274.
[8] K.D. McNeil, A. Firooz-Abadi, W. Oliver, P.V. Zimmerman, Amiodarone pulmonary toxicity–three unusual manifestations, Aust. N. Z. J. Med. 22 (1992) 14–18.
[9] J. Miyaki, S. Souma, Y. Narumiya, S. Chiba, A case of unilateral organizing pneumonia induced by amiodarone pulmonary toxicity, Nihon Kōyūki Gakkai Zasshi 47 (2009) 393–398.
[10] J. McGrane, M. Paravasthu, W. Candlish, J. Gravil, Unilateral balsalazide-induced eosinophilic pneumonia in an ulcerative colitis patient, J. R. Coll. Physicians Edinb. 40 (2010) 216–218.
[11] K. Saltzman, L.J. Rossoff, H. Gouda, S. Tongia, Mesalamine-induced unilateral eosinophilic pneumonia, AJR Am. J. Roentgenol. 177 (2001) 257.
[12] K. Tada, Y. Kuribara, T. Myojo, F. Kojima, Y. Ishikawa, N. Yoshiyasu, et al., Case report of nivolumab-related pneumonitis, Immunotherapy 9 (2017) 313–318.
[13] T. Izumo, M. Kondo, M. Mae, S. Onizawa, N. Nagara, T. Nozu, et al., A case of loxoprofen sodium-induced eosinophilic pneumonia that occurred ipsilaterally after VATS lobectomy for lung cancer, Nihon Kōyūki Gakkai Zasshi 45 (2007) 799–803.
[14] Y. Goda, T. Shoji, H. Katakura, Unilateral antibiotic-induced acute eosinophilic pneumonia on the operative side after surgery for primary lung cancer: a case report, Surg. Case Rep. 6 (2020) 40.
[15] Y. Masuda, T. Yamada, T. Marutsuka, T. Saisho-ji, A case of unilateral eosinophilic pneumonia following lung resection for lung cancer caused by fibrin sealant, Jpn J. Chest Surg. 28 (2014) 471–476.
[16] N. Miyashita, M. Nakajima, M. Kuroki, S. Kawabata, K. Hashiguchi, Y. Niki, et al., Sulbactam/ampicillin-induced pneumonitis, Ann. Japanese Respir Soc. 36 (1998) 684–689.
[17] D.A. Salerno, Sirolimus lung toxicity as a unilateral lung infiltrate, Chest 128 (2005) 444.
[18] F. Strasser, S. Hailermariam, M. Hausser, B.C. Pestalozzi, A 53-year-old patient with unilateral pulmonary infiltrates following a single dose of mitomycin, vindesine and cisplatin chemotherapy for non-small-cell lung cancer, Respiration 66 (1999) 562–572.
[19] X. Hu, J.S. Lee, P.T. Pianosi, J.H. Ryu, Aspiration-related pulmonary syndromes, Chest 147 (2015) 815–823.
[20] R.M. Mehta, N. Rashmi, P. Baja, S. Krishnan, L. Srinivasan, Airway stenosis related to foreign body aspiration: an under-recognized long term complication, Clin. Med. Insights Case Rep. 12 (2019), 1179547619863816.